Pharmacy Times – August 2012


Drug Interactions: Insights and Observations


Metoclopramide and Dyskinesia: The Role of Drug Interactions


John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD





1. Albibi R, et al. Metoclopramide: pharmacology and clinical application. Ann Inter Med. 1983;98:86-95.

2. Tonini M et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19:379-90.

3. Wright MR et al. Linearity of metoclopramide kinetics at doses of 5-20 mg. Br J Clin Pharmacol. 1988;26:469-73.

4. Desta Z, et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30:336-43.

5. Yu J et al. In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos. 2006;34:1386-92.

6. van der Padt A et al, Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med. 2006;64:160-2.

7. Parkman HP et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494-503.

8. Doran A et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-74.

9. Vlase L et al. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos. 2006;27:285-9.